ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018
When is crossover desirable in cancer drug trials and when is it problematic?
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials.Radiation oncology (London, England) · 2024Pooled it
- Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.BMC cancer · 2022Pooled it
- Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.JAMA network open · 2021Pooled it
- Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review.JAMA network open · 2021Pooled it
- Trial
- Crossover does not confound, it informs:Nature reviews. Clinical oncology · 2026Article
- Review
- Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA Submissions.Journal of health economics and outcomes research · 2026Article
- Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework.The oncologist · 2025Review
- ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology.JHEP reports : innovation in hepatology · 2025Article
- Behavioral and neural effects of temporoparietal high-definition transcranial direct current stimulation in logopenic variant primary progressive aphasia: a preliminary study.Frontiers in psychology · 2025Article
- Review
- Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?Current treatment options in oncology · 2024Review
- Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials.BMJ oncology · 2024Article
- Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.Seminars in radiation oncology · 2023Review
- Review
- Article
- Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.European urology open science · 2023Article
- Clinical Benefit Scales and Trial Design: Some Statistical Issues.Journal of the National Cancer Institute · 2022Review
- Overall survival as a primary end point in multiple myeloma trials.Nature reviews. Clinical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.